title: Nodular lymphocyte-predominant hodgkin lymphoma.
abstract: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a distinct subtype of Hodgkin lymphoma, is a rare disease with a generally favorable prognosis. The hallmark of NLPHL is the presence of the lymphocytic and histiocytic cell, which, in contrast to the classic Reed-Sternberg cell, is CD20+, CD15-, and CD30-. NLPHL tends to have an indolent natural history, a long time to disease progression, a delayed time to relapse, and a high likelihood of presenting as early-stage disease. The evidence to guide the management of patients with NLPHL is limited by the rarity of this disease, but the available data support the use of involved-field radiation therapy alone for localized disease. Treatment-related late effects contribute significantly to the causes of death in patients treated for NLPHL.
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
authors.forename: Henry K
authors.initials: HK
authors.lastname: Tsai
authors.forename: Peter M
authors.initials: PM
authors.lastname: Mauch
mesh_terms: D018951:Antigens, CD20 / Q000032:analysis; D018450:Disease Progression; D006644:Histiocytes / Q000473:pathology; D006689:Hodgkin Disease / Q000145:classification* / Q000532:radiotherapy; D006801:Humans; D016256:Lewis X Antigen / Q000032:analysis; D008214:Lymphocytes / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D035583:Rare Diseases
chemical_list: D018951:Antigens, CD20; D016256:Lewis X Antigen